Methods for the diagnosis of fetal abnormalities

US10041119B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10041119-B2
Application numberUS-201514705239-A
CountryUS
Kind codeB2
Filing dateMay 6, 2015
Priority dateJun 14, 2006
Publication dateAug 7, 2018
Grant dateAug 7, 2018

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention relates to methods for detecting, enriching, and analyzing rare cells that are present in the blood, e.g. fetal cells. The invention further features methods of analyzing rare cell(s) to determine the presence of an abnormality, disease or condition in a subject, e.g. a fetus by analyzing a cellular sample from the subject.

First claim

Opening claim text (preview).

What is claimed is: 1. A method for determining the presence or absence of a fetal trisomy or monosomy using a maternal blood sample comprising a mixture of fetal and maternal genomic nucleic acids, the method comprising: obtaining a test sample comprising a mixture of fetal and maternal genomic nucleic acids from a maternal blood sample; selectively amplifying a plurality of target nucleic acids from the test sample and a plurality of target nucleic acids from a reference sample, wherein the target nucleic acids are selected from one or more chromosomes to be tested for trisomy or monosomy, and wherein the reference sample is diploid for the one or more chromosomes to be tested for trisomy or monosomy; detecting the amplified target nucleic acids from the test sample and from the reference sample; quantifying the target nucleic acids from the test sample and from the reference sample by highly parallel sequencing; analyzing the test sample for the presence or absence of a fetal trisomy or monosomy by comparing the quantity of the detected amplified target nucleic acids obtained from the test sample for the one or more chromosomes tested for trisomy or monosomy to the quantity of the detected amplified target nucleic acids obtained from the reference sample for the one or more chromosomes tested for trisomy or monosomy; and generating a report on the presence or absence of trisomy or monosomy in the maternal blood sample. 2. The method of claim 1 , wherein the maternal blood sample is from a pregnant woman. 3. The method of claim 1 , wherein the fetal and maternal genomic nucleic acids are enriched from the maternal blood sample. 4. The method of claim 1 , wherein the target nucleic acids are selected from one or more of chromosomes X, Y, 13, 18, and 21. 5. The method of claim 1 , wherein the highly parallel sequencing is selected from high-throughput sequencing, ultra-deep sequencing, and sequencing-by-synthesis. 6. The method of claim 1 , wherein the fetal trisomy is trisomy 13, trisomy 18, or trisomy 21. 7. The method of claim 1 , wherein the target nucleic acids are SNPs, STRs, or RNA transcripts. 8. The method of claim 1 , wherein the amplification comprises: hybridizing two or more oligonucleotide probes to each of the target nucleic acids; ligating the two or more hybridized oligonucleotide probes at each of the target nucleic acids to create amplification templates for each of the target nucleic acids; and amplifying the amplification templates. 9. The method of claim 8 , further comprising attaching biotin to the target nucleic acids to generate biotin-labeled target nucleic acids. 10. The method of claim 9 , further comprising attaching the biotin-labeled target nucleic acids to streptavidin. 11. The method of claim 1 , wherein quantifying the target nucleic acids further comprises determining gene or allele copy number or both gene and allele copy number. 12. The method of claim 11 , further comprising determining fetal trisomy or monosomy based on the gene or allele copy number or gene and allele copy number determination.

Assignees

Inventors

Classifications

  • Primer sets for multiplex assays · CPC title

  • Expression markers · CPC title

  • Staining; Impregnating {; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis} · CPC title

  • Polymorphic or mutational markers · CPC title

  • C12Q1/6883Primary

    for diseases caused by alterations of genetic material · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10041119B2 cover?
The present invention relates to methods for detecting, enriching, and analyzing rare cells that are present in the blood, e.g. fetal cells. The invention further features methods of analyzing rare cell(s) to determine the presence of an abnormality, disease or condition in a subject, e.g. a fetus by analyzing a cellular sample from the subject.
Who is the assignee on this patent?
Verinata Health Inc, Massachusetts Gen Hospital, Gpb Scientific Llc
What technology area does this patent fall under?
Primary CPC classification C12Q1/6883. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Aug 07 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).